For the second time in just under a year, Nektar Therapeutics is restructuring, this time reducing headcount roughly 60% to about 55 people at its San Francisco headquarters, putting internal R&D emphasis on immunology and seeking to partner out its lead cancer candidate, the Phase II interleukin-15 (IL-15) receptor agonist NKTR-255. The biotech said on 17 April that it will prioritize development of IL-2-targeted rezpegaldesleukin (rezpeg) in autoimmune and inflammatory conditions regardless of whether partner Eli Lilly and Company continues its participation.
[Sidebar#SC146286]








